Allurion receives further notice from NYSE regarding listing standards Page 1

Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company committed to ending obesity, today announced that it has received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it does not comply with the NYSE’s standards for a continuous listing because the Company’s average market capitalization for the 30 consecutive trading days ending August 29, 2024 was less than $50.0 million and the Company’s last reported equity as of August 29, 2024 was less than $50.0 million. The Notice will not result in the immediate delisting of the Company’s common stock from the NYSE.

Pursuant to the NYSE’s procedures, the Company intends to submit to the NYSE, within 45 days of receipt of the Notice, a plan disclosing the definitive actions the Company has taken, is taking or plans to take to ensure compliance with the standards for continued listing. If the NYSE accepts the Company’s plan, the Company’s common stock will continue to be listed and traded on the NYSE during the 18-month cure period, subject to the Company’s compliance with other standards for continued listing and ongoing periodic review by the NYSE of the Company’s progress with respect to its plan.

The announcement will not have an immediate impact on the listing of the Company’s common stock, which will continue to be listed and traded on the NYSE during the cure period, provided that the Company complies with other standards for continued listing on the NYSE. In addition, the announcement is not expected to have an impact on the Company’s ongoing business operations or its reporting obligations to the U.S. Securities and Exchange Commission.

About Allurion
Allurion is committed to combating obesity. The Allurion Program is a weight loss platform that includes the Allurion gastric balloon, the world’s first and only swallowable non-invasive weight loss balloon, and provides access to the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for healthcare providers with the Coach Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available separately from the Allurion Program for providers to customize, monitor and manage weight loss therapy for patients regardless of their treatment plan (gastric balloon, surgical, medical or nutritional). The Allurion gastric balloon is an investigational device in the United States.